Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis. (Q53064328)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 June 2016

Language	Label	Description	Also known as
English	Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.	scientific article published on 6 June 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

1 reference

based on heuristic

inferred from title

Giorgina Specchia

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Francesco Albano

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Silvana Capalbo

object named as

Silvana Franca Capalbo

6

0 references

author name string

Patrizio Mazza

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Nicola Di Renzo

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Nicola Cascavilla

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Giuseppe Tarantini

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Tiziana Urbano

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Reddiconto Giovannni

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Antonietta Pia Falcone

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Maria Teresa Santeramo

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Giuseppina Spinosa

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Salvatore Pisconti

13

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

publication date

6 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

58

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

138-144

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

New mutations and pathogenesis of myeloproliferative neoplasms.

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Practical management of myelofibrosis with ruxolitinib.

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2016.1189547

21 January 2018

Identifiers

10.1080/10428194.2016.1189547

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27263544

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53064328&oldid=1516987944"